Kolon TissueGene, Inc.
- Biotech or pharma, therapeutic R&D
Kolon TissueGene specialize in developing advanced treatments for degenerative joint and spinal diseases, including osteoarthritis and degenerative disc disease, based on innovative cell and gene therapies. Our flagship product, TG-C, is a novel, genetically engineered allogeneic cell therapy currently undergoing two pivotal Phase 3 clinical trials in the U.S., involving over 1,000 patients with knee osteoarthritis. A two-year follow-up period is currently underway, with topline results expected around mid-2026. Due to the high prevalence of osteoarthritis and TG-C's competitive advantages in the multi-billion-dollar global OA treatment market, third-party market research firms project that peak sales of TG-C for knee OA in the U.S. alone could exceed $3 billion
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}